The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world effectiveness of palonosetron within a three-drug regimen to prevent chemotherapy induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
 
Robert B. Geller
Employment - HERON
Stock and Other Ownership Interests - HERON
Consulting or Advisory Role - Lilly
Travel, Accommodations, Expenses - HERON
 
Trent McLaughlin
Employment - AmerisourceBergen
 
Kimberly McLeod
Employment - AmerisourceBergen
 
Madhuri Bajaj
No Relationships to Disclose
 
Shaker R. Dakhil
No Relationships to Disclose
 
Eduardo Braun
Employment - Michael and Sherry Sutton Fund for Urothelial Cancer
Consulting or Advisory Role - Genentech; HERON
Speakers' Bureau - Genentech; Merck
Research Funding - HERON
 
David T. Chu
No Relationships to Disclose
 
Nashat Y. Gabrail
Speakers' Bureau - Boehringer Ingelheim; Janssen; Onyx; Sanofi
Research Funding - Boehringer Ingelheim (Inst); Janssen (Inst); Onyx (Inst); Sanofi (Inst)
 
Stanley M. Marks
Honoraria - Celgene; Merck
Consulting or Advisory Role - Lilly
Speakers' Bureau - Celgene; Merck
 
Lee Steven Schwartzberg
Leadership - Vector Oncology
Stock and Other Ownership Interests - Vector Oncology
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Genentech; Teva
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Novartis
Research Funding - Eisai